Nkgen Biotech Inc. Announces Sale of 19.67 Million Shares and Issuance of Warrants for Additional 39.34 Million Shares in $2.5 Million Deal with CFIC-2015 NV Family Investments, LLC

Reuters05-20
Nkgen Biotech Inc. Announces Sale of 19.67 Million Shares and Issuance of Warrants for Additional 39.34 Million Shares in $2.5 Million Deal with CFIC-2015 NV Family Investments, LLC

NKGen Biotech Inc. has entered into a Stock Purchase Agreement with CFIC-2015 NV Family Investments, LLC. Under this agreement, NKGen will issue and sell 19,669,552 shares of its common stock at a purchase price of $0.1271 per share, totaling an aggregate purchase price of $2,500,000. Additionally, a warrant to purchase up to 39,339,103 shares of common stock at the same share price will be issued to the purchaser. The transaction is pending the purchaser's payment of the purchase price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-045648), on May 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment